Direct tumor attack: new method aims to boost pancreatic cancer surgery success
NCT ID NCT07477418
Summary
This study is testing a new way to deliver a standard chemotherapy drug (gemcitabine) directly to pancreatic tumors before surgery. The goal is to see if this targeted delivery method is safe and can help surgeons remove more of the cancer with cleaner margins. It is for people with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who have not yet received treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.